Schizophrenia (SCZ) has a strong genetic component^[@R1],[@R2]^. Despite the high heritability, a large fraction of SCZ cases do not have a family history of the disease (sporadic cases)^[@R3]^. Although largely ignored in earlier efforts to model disease risk, *de novo* germline mutations may account for a significant fraction of sporadic SCZ cases. In agreement with this hypothesis, rare *de novo* copy number variants (CNVs)^[@R4]^ are emerging as an important genomic cause of psychiatric disease and the variant with strongest statistical support for association with SCZ, namely the 22q11.2 microdeletion, is a *de novo* and recurrent mutation^[@R5],[@R6]^.

Availability of next-generation whole genome or exome sequencing^[@R7]^ now permits the study of *de novo* mutations \[point substitutions (or single nucleotide variants, SNVs) and small insertions/deletions (in/dels)\] in a systematic genome-wide manner^[@R8],[@R9]^. Pilot studies in patients with SCZ focusing on specific synaptic genes identified a small number of putative *de novo* mutations ^[@R10]^. However, the full contribution of rare *de novo* SNVs and in/dels to SCZ remains unknown. In this study, we use family-based whole-exome sequencing to test the hypothesis that *de novo* protein-altering mutations contribute substantially to the genetic component of SCZ.

We sequenced the exomes of 53 family trios of subjects diagnosed with SCZ or schizoaffective (SCZAFF) disorder, with no history of the disease in a first- or second-degree relative ('sporadic cases cohort') as well as family trios from 22 unrelated healthy controls, all recruited from the European descent genetically homogeneous Afrikaner population in South Africa^[@R11],[@R12]^. Presence or absence of family history in cases was not a screening criterion during recruitment but could be reliably determined because of the close-knit family structure of the families and the availability of detailed psychiatric records over several generations due to the large catchment area and long-term care provided by the local recruiting hospital^[@R6],[@R12],[@R13]^. Control families completed a detailed self-report questionnaire that inquired about several psychiatric conditions, including phobias, anxiety, depression and history of treatment for any of these conditions. Also, mental illness in first- or second-degree relatives was excluded. Based on previous results^[@R6],[@R13]^ we excluded carriers of rare *de novo* CNVs. Identities were coded and analysis was performed blind to affected status while maintaining knowledge of the parent-child relations. From all 225 individuals we extracted DNA samples from whole blood.

We enriched exonic sequences using the Agilent SureSelect technology for targeted exon capture and performed Illumina paired-end sequencing (one lane of flow-cell per sample, see **Methods**). On average, we obtained 7.3 Gb of mappable sequence data per individual after exome enrichment, targeting 37 Mb from exons and their flanking regions. Overall, we covered 1.22% of the genome, a fraction corresponding to the NCBI Consensus Coding Sequences database (CCDS). The paired-end reads were cross-matched to the reference genome (hg19 build) using the Burrows-Wheeler Aligner (BWA v0.5.81536)^[@R14]^. 97.9% of the reads were properly aligned to the reference genome. Our median read depth is 65.2X, which is higher than the estimated average depth (33X) required for highly accurate downstream heterozygous variant detection. In addition, 92.4% of the captured target exons were covered by high quality genotype calls at least 8 times to ensure good detection sensitivity^[@R15]^ ([Table 1](#T1){ref-type="table"}).

Our *de novo* mutation detection pipeline is depicted in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}. We implemented a series of filters, including final validation by standard Sanger sequencing ([Supplementary Figure 2 and 3](#SD1){ref-type="supplementary-material"}), to eliminate variants that would appear *de novo* either from under-calling in the parents or systematic false positive calls in the subjects (see **Methods**). In total, in the affected trios we observed 34 *de novo* point mutations (33 SNVs and 1 dinucleotide substitution) and 4 *de novo* in/del candidates ([Table 2](#T2){ref-type="table"}). Overall, 27 out of 53 patients (\~51%) carry at least one *de novo* mutational event. This rate is comparable to the one reported for 20 parent-child trios with autism spectrum disorders (51%)^[@R8]^, but somewhat lower compared to the one reported for 10 parent-child trios with intellectual disability (90%)^[@R9]^. Ten of the 27 patients carried more than one *de novo* mutation and the rest each carried a single mutation or in/del. Among the 34 *de novo* point mutations, 32 were predicted to be non-synonymous missense mutations and only 2 synonymous. Of the 32 non-synonymous mutations, 19 affect evolutionarily conserved residues and are predicted to affect protein function by PolyPhen-2. Three of the in/dels result in protein truncations and 1 in single aminoacid deletion. Additional query of *de novo* SNVs located within the flanking intronic regions identified 2 SNVs located within predicted donor/acceptor splice sites ([Table 2](#T2){ref-type="table"}). Interestingly, among the identified exonic SNVs, 1 synonymous and 3 non-synonymous ones were also located within predicted donor/acceptor splice sites ([Table 2](#T2){ref-type="table"}). Further analysis using the HSF tool (<http://www.umd.be/HSF/>) showed that 2 out of 6 mutations directly alter splice signals and may interfere with splicing ([Table 2](#T2){ref-type="table"}). By our filtering criteria all identified *de novo* mutations are absent in a total of 1,658 control chromosomes (the exomes of the 679 individuals from the 1,000 Genomes Project^[@R16]^ included in dbSNP132, as well as of all 150 unaffected parents in our 2 cohorts). Using the same pipeline and filtering criteria, we identified 7 exonic *de novo* SNVs but no in/del candidates in 7 out of 22 control subjects. Among these 7 *de novo* point mutations, 4 are predicted to be non-synonymous missense and 3 synonymous. In addition, we identified 1 *de novo* mutation within a predicted intronic splice site ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Overall, 7 out of 22 controls carry at least one *de novo* event, with one control carrying more than one *de novo* mutation. The fraction is lower when compared to cases but the difference is not statistically significant (Fisher's Exact Test*, P* value = 0.2). There was no difference in the coverage between cases and controls and between trios with and without *de novo* events ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}).

The overall *de novo* rate in affected families (0.75 events per family) is comparable to several empirical estimates of the background *de novo* mutation rate^[@R8],[@R16]^, suggesting that we identified most of the *de novo* events in these trios. Several lines of evidence suggest that the identified mutations have a high likelihood of causation with respect to SCZ. First, our screen yielded a ratio of non-synonymous missense (*n* = 32) to synonymous (*n* = 2) *de novo* changes (NS/S ratio) of 16:1, which is considerably higher than the 2.85:1 ratio expected based on the probability of causing an aminoacid change under a random model (71.25% non-synonymous missense substitutions and 25% synonymous^[@R17]^ ). By contrast, the ratio of non-synonymous missense (*n* = 4) to synonymous (*n* = 3) *de novo* changes in the control cohort (NS/S ratio of 1.33:1) is consistent to neutral expectation and very close to the NS/S ratio reported by the 1,000 Genome Project (1.14 -- 1.45)^[@R16]^. Second, non-synonymous *de novo* point mutations were found in large excess compared to neutral ones relative to rare inherited variants, which are less likely to contribute to the pathogenesis of the sporadic cases ([Table 3](#T3){ref-type="table"}). Specifically, we first compared the relative enrichment of non-synonymous *de novo* point mutations to the one observed among all novel (i.e. not observed in dbSNP132) inherited variants segregating in cases. Our analysis revealed a NS/S substitution ratio of 1.61:1, consistent with previous analysis of normal genetic variation^[@R16],[@R18]^. Thus, in sporadic SCZ cases, rare *de novo* variants are \~10 times more likely than inherited rare variants to harbor non-synonymous changes (Chi-square test, *P* = 0.0002). A similar analysis in the control cohort did not reveal significant differences. The NS/S ratio was 1.33 and \~1.60 for rare *de novo* and inherited variants, respectively (relative enrichment 0.83; Chi-square, *P* = 0.81). We obtained similar results when we limited the analysis to the private inherited variants (i.e. present only in one affected family), which serve as a proxy for evolutionarily young mutation events. This analysis yielded a NS/S ratio of \~ 1.69:1 in cases (relative enrichment 9.5; Chi-square test, *P* = 0.0003) and \~1.74 in controls (relative enrichment 0.76; Chi-square test, *P* = 0.73). Consistent with expectations that disease mutations have a greater impact on protein function^[@R19]^, we observed a more striking enrichment when we restricted our analysis to non-synonymous SNVs predicted by PolyPhen-2 to affect protein function. For such changes, the NS/S ratio in SCZ cases is 9.5 and \~ 0.79 for rare *de novo* and private inherited variants, respectively (relative enrichment 12.1; Chi-square test, *P* \< 0.0001).

We explored further the possibility that *de novo* mutations in cases have a greater potential to affect protein structure and function than private inherited variants by examining the evolutionary conservation of affected nucleotides (using the phyloP score^[@R20]^), as well as the potential of the *de novo* protein-altering mutations to affect the structure or function of the resulting proteins (using the Grantham score^[@R21]^) ([Table 2](#T2){ref-type="table"}). When we compared the cumulative distribution of these scores between *de novo* and private inherited variants in the sporadic cases cohort ([Figure 1](#F1){ref-type="fig"}) we observed that the distribution of the *de novo* variants was clearly shifted to the right (phyloP, *P* = 0.0005; Grantham, *P* = 0.14). Overall, our analysis reveals an enrichment of highly conserved and disruptive aminoacid mutations among *de novo* events and suggests a high likelihood for pathogenicity. Notably, carriers of one or more *de novo* mutations appear to be indistinguishable from other SCZ patients in terms of sex distribution, clinical presentation and developmental course (see [Supplementary Information](#SD1){ref-type="supplementary-material"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

All mutations occurred in different genes, precluding statistical assessment for any specific locus. Identification of recurrent mutations will provide definitive proof for disease causality. With one exception, none of the affected genes have been previously associated with genetic loci or biological pathways unequivocally associated with SCZ. We therefore used phyloP and Grantham scores as a guide to prioritize for further discussion events that are more likely to be causal. In addition to protein truncating in/dels (in *LAMA2, SPATA5, RB1CC1)* there are 12 SNVs with phyloP scores ≥ 4 and 9 SNVs with Grantham score ≥ 100, while 3 SNVs (in *DGCR2*, *KLF12* and *PLCL2*) show high values for both scores (see [Table 2](#T2){ref-type="table"}). Most notable among the putative pathogenic events is a p.Pro429Arg substitution in *DGCR2* in a male patient with SCZ (see [Supplementary Information](#SD1){ref-type="supplementary-material"}). *DGCR2* is located in the 22q11.2 locus and is hemizygously deleted by recurrent *de novo* microdeletions at this locus, which have high penetrance (\~30%) and account for up to 2% of sporadic SCZ cases. The gene encodes a putative transmembrane adhesion receptor of unknown function^[@R22]^. The p.Pro429Arg substitution is located within a conserved domain of the protein ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}) and shows one of the highest Grantham and phyloP scores among all identified changes. Identification of a disruptive *de novo* SNV in the *DGCR2* gene, in a patient with structurally intact 22q11.2 chromosomes suggests that disruption of this gene may be contributing to the elevated SCZ risk associated with the 22q11.2 locus. Whether heterozygous deletions or point mutations in the *DGCR2* are sufficient to render the susceptibility to SCZ observed in 22q11.2 microdeletion carriers or whether additional genetic interactions are required^[@R23]^, cannot be resolved until more *DGCR2* mutations are identified and their penetrance is determined. Additional putative pathogenic events were identified in three G-protein coupled receptors (GPRs: *GPR153*, *GPR115* and *OR4C46*)^[@R24],[@R25]^ as well as in genes encoding proteins thought to either modulate (i.e. *RGS12*) or mediate aspects of GPR signaling, such as regulation of cAMP levels (i.e. *ADCY7*^[@R26]^). Notably, we have recently reported an association between SCZ and structural *de novo* mutations in another GPR (*VIPR2*)^[@R27]^ and showed that these mutations alter cAMP levels. For other genes with high phyloP or Grantham scores. such as *WDR11*, *PLCL2, TRAK1, KLF12 and LAMA2*, evidence for a potential causal link with SCZ is provided by literature on previously described mutations, model organisms and other functional studies ([Supplementary Information](#SD1){ref-type="supplementary-material"}).

Our work conclusively demonstrates that *de novo* protein-altering mutations contribute substantially to the genetic component of SCZ and, taken together with previous estimates of the *de novo* CNV rate in the same population^[@R6]^, it indicates that *de novo* mutations account for more than half of the sporadic cases of SCZ. Our findings are also in line with results from genome-wide scans for *de novo* CNVs^[@R6],[@R28]^ or CNVs in general^[@R29],[@R30]^ supporting the notion that multiple *de novo* genetic variants that affect many different genes contribute to the genetic risk of SCZ. The complexity of the neural substrates affected in SCZ and other psychiatric disorders offers a large mutational target comprised of many genes. We propose that this large number of targets that, when mutated, can give rise to SCZ along with the relatively high rate of protein-altering mutations, empirically demonstrated in the present study, provides a plausible explanation for both the high global incidence and the persistence of SCZ despite extremely variable environmental factors, severely reduced fecundity and increased mortality. Our findings represent a decisive step towards understanding the pathogenesis of the disease and emphasize the challenge in determining the neural substrates that these diverse genetic risk factors converge upon to generate a common pattern of clinical dysfunction and symptoms^[@R23],[@R31]--[@R34]^.

METHODS {#S1}
=======

Cohorts {#S2}
-------

All 53 SCZ families were recruited from the Afrikaner population in South Africa and heritage was established by surname and by having 4 Afrikaans-speaking grandparents. Informed consent was obtained from all participants. The Institutional Review Committees of Columbia University and University of Pretoria approved all procedures. Diagnostic evaluations were done in person, as previously described^[@R6],[@R13]^. Family history was obtained from the proband, each participating parent, and additional relatives as needed, by two independent raters, a nursing sister, who recorded pedigree information, and by the clinical interviewer, who inquired in detail about family history during the clinical interview^[@R6],[@R13]^. For additional cohort characteristics, see [Supplementary Information](#SD1){ref-type="supplementary-material"}. The control cohort consisted of 22 families (triads) with established Afrikaner heritage recruited from the Afrikaner community. Paternity and maternity were confirmed prior to sequencing for all case and control families via the Affymetrix Genome-Wide Human SNP Array 5.0^[@R6],[@R13]^ as well as via a panel of microsatellite markers.

Exome library construction {#S3}
--------------------------

Exome enrichment was conducted using the SureSelect Human All Exon Target Enrichment System (Agilent Technologies) based on the methodology described in^[@R35]^. Briefly, 3 ug of genomic DNA was fragmented by sonication using the Covaris S2 to achieve a uniform distribution of fragments with a mean size of 300 bp. The sonicated DNA was purified using Agencourt's AMPure XP Solid Phase Reversible Immobilization paramagnetic bead (SPRI) followed by polishing of the DNA ends by removing the 3′ overhangs and filling in the 5′ overhangs resulting from sonication using T4 DNA polymerase and Klenow fragment (New England Biolabs). Following end polishing, a single 'A'-base was added to the 3′ end of the DNA fragments using Klenow fragment (3′ to 5′ exo minus). This prepares the DNA fragments for ligation to specialized adaptors that have a 'T'-base overhang at their 3′ends. The end-repaired DNA with a single 'A'-base overhang is ligated to the Illumina paired-end adaptors in a standard ligation reaction using T4 DNA ligase and 2 uM -- 4 uM final adaptor concentration, depending on the DNA yield following purification after the addition of the 'A'-base. Following ligation, the samples were purified using SPRI beads, quality controlled by assessment on the Agilent Bioanalyzer and then amplified by 6 cycles of PCR to maintain complexity and avoid bias due to amplification.

Library capture and sequencing {#S4}
------------------------------

500 ng of amplified, purified DNA (DNA library) was prepared for hybridization by adding the DNA library to Agilent blocking reagents, denaturing at 95 °C and incubating at 65 °C. All subsequent steps were performed at 65 °C. Hybridization buffer was added to the prepared library and the entire mix was then added to an aliquot of the Agilent SureSelect Capture Library and mixed. The DNA library and biotin-labeled Capture Library were hybridized by incubation at 65 °C for 24 hours. Following hybridization, streptavidin coated magnetic beads were used to purify the RNA:DNA hybrids formed during hybridization. The RNA capture material was digested via acid hydrolysis following elution from the purification beads. The neutralized captured DNA was purified, desalted and amplified by 12 cycles of PCR using Herculase II Fusion DNA polymerase. The libraries were purified following amplification and the library was assessed using the Agilent Bioanalyzer. A single peak between 300 -- 400 bp indicates a properly constructed and amplified library ready for sequencing. Final quantitation of the library was performed using the Kapa Biosciences Real-time PCR assay and appropriate amounts of the library were loaded onto the Illumina flowcell for sequencing by paired-end 50 nt sequencing on the Illumina HiSeq2000 instrument. Sequencing was performed largely as described in^[@R16]^. Following dilution to 10 nM final concentration based on the real-time PCR and bioanalyzer results, the final library stock was then used in paired-end cluster generation at a final concentration of 6 -- 8 pM to achieve a cluster density of 600,000/mm^2^ (on the Illumina HiSeq2000 instrument). Following cluster generation, 50 nt paired-end sequencing was performed using the standard Illumina protocols.

Exome data analysis for *de novo* coding point mutations, in/dels and splice site mutations {#S5}
-------------------------------------------------------------------------------------------

Raw sequencing data for each individual were mapped to the human reference genome (build hg19) using the Burrows-Wheeler Aligner (BWA v0.5.81536)^[@R14]^. The BWA aligned sequencing reads were processed by Picard (<http://picard.sourceforge.net/>) to label the PCR duplicates. The Genome Analysis Toolkit (GATK, version 5091) was then used to remove duplicates, perform local realignment and map quality score recalibration to produce a "cleaned" BAM file for each individual. SNP calls were made by the Unified Genotyper module in GATK using the "cleaned" BAM files in batch fashion (90 samples per batch). The resulting Variant Call Format (VCF, version 4.0) files were annotated using the GenomicAnnotator module in GATK to identify and label the called variants that are within the targeted coding regions and overlap with known and likely benign SNPs reported in dbSNP v132 (<ftp://ftp.ncbi.nlm.nih.gov/snp/organisms/human_9606/VCF/v4.0/00-All.vcf.gz>). The annotated VCF files were then filtered using the GATK variant filter module with a hard filter setting and a custom script for initial filtering. Variant calls that failed to pass the following filters were eliminated from the call set: i) MQ0 \>= 4 && ((MQ0/(1.0 \* DP)) \> 0.1); ii) QUAL \< 30.0 \|\| QD \< 5.0 \|\| HRun \> 5 \|\| SB \> 0.00; iii) Cluster size 10; iv) Contain dbSNP id; v) Outside the targeted regions. Combined VCF files were then split into individual files and variants in each offspring were compared to variants present in parents using a custom script pipeline in order to determine the inheritance pattern and annotate *de novo* mutations.

Because the GATK Unified Genotyper is set to maximize the sensitivity of variant calls, it allows for a significant portion of false positives among candidate variants even following the initial filtering process. To address this issue and eliminate potential false positive calls in the offspring and false negative calls in the parents, we took advantage of the inheritance information provided by our family design and revalidated all variants identified using the mpileup module in the SAM tools (<http://samtools.sourceforge.net/>) according to the following rules: i) the forward reference (fr) count (i.e. the number of forward reads that match the reference base at this locus), the reverse reference (rr) count (i.e. the number of reverse reads that match the reference base at this locus), the forward non reference (fnr) count (i.e. the number of forward reads that do not match the reference base at this locus) and the reverse non reference (rnf) count (i.e the number of reverse reads that do not match the reference base at this locus) in the offspring must be 2 or greater; ii) total read depth in both parents must be 10 or greater; iii) both fr and rr count in both parents must be 2 or greater; iv) either fnr or rnr count in both parents must be 0; v) The fnr and rnr count to total count ratio in the parental population (defined as all 150 parental samples sequenced) must be less than 1/2n, where n is the population size; vi) If any of rules 1--5 was violated, the sequence information was considered insufficient to make a *de novo* call at this locus.

In/del calls were made by the Dindel software using one "cleaned" BAM file per run. The resulting VCF files were used to determine inheritance patterns using the same procedure described above for point mutations. To determine potential mutations at splice-donor or acceptor sites, GATK variant calls were made in a batch fashion (with 90 samples per batch) that covered each target coding region and 50 bp flanking segments in each direction. The variants in the resulting VCF files were annotated according to <ftp://gatk-ftp:PH5UH7Pa@ftp.broadinstitute.org/refGene/refGene-big-table-hg19.txt.gz>.

The PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>) online server was used to determine the non-synonymous and synonymous nature of the mutations and predict their functional impact by further classifying them as non-tolerated (damaging) or benign at a given site. The Grantham score for each coding variant was determined by the Grantham matrix table^[@R21]^. The phyloP score for each coding variant was extracted from the "phyloP46wayAll" table in the UCSC Table Browser (<http://genome.ucsc.edu/cgi-bin/hgTables>). The Human Splicing Finder (HSF, Version 2.4.1) software (<http://www.umd.be/HSF/>) was used to predict potential functional impact of the mutations at splice sites.

Statistics {#S6}
----------

The Kolmogorov-Smirnov test (KS-test) was used to compare the distribution of phyloP and Grantham scores among *de novo* or private inherited mutations in cases. The KS-test was conducted using R ([www.r-project.org/](www.r-project.org/)). Fisher's exact test or Chi-square test with Yates' correction was used for the analysis of contingency tables depending on the sample sizes.

*De novo* mutation validation {#S7}
-----------------------------

Candidate *de novo* variants were tested using standard Sanger sequencing on an ABI 3730xl DNA Analyzer to validate presence of each mutation in the subjects and absence in the parental genomes, by designing custom primers (Sigma) based on \~500 bp of genomic sequence flanking each variant. *De novo* occurrence of mutations was not confirmed in 6 out of 46 and 2 out of 9 candidate alterations in cases and controls, respectively.

Supplementary Material {#S8}
======================
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###### 

Overview of exome sequencing data production

                            Average         Percent
  ------------------------- --------------- ---------
  Total Sequence (bp)       7,475,900,117   100.00%
  Aligned Sequence (bp)     7,319,357,510   98.34%
  Aligned Paired reads      69,747,339      97.55%
  Aligned Singleton reads   566,300         0.35%
  Median Read Depth         65.2 X          
  1x Coverage               37,191,631      98.84%
  4x Coverage               36,190,388      96.18%
  8x Coverage               34,769,095      92.40%
  20x Coverage              30,428,158      80.87%
  30x Coverage              27,171,231      72.21%

###### 

*De novo* mutations identified in 53 SCZ trios

  Gene Symbol   Mutation Type   NS vs S                                    Polyphen-2          Grantham Score                       phyloP Score   Chr:Pos        Nucleotide change     Aminoacid change   Diagnosis    Sex   Trio ID
  ------------- --------------- ------------------------------------------ ------------------- ------------------------------------ -------------- -------------- --------------------- ------------------ ------------ ----- ----------
  *PLCL2*       SNV             NS                                         probably damaging   112                                  4.99           3:17051253     TGT-aGT               p.Cys30Ser         SCZ          M     trio_002
  *WDR11*       SNV             NS                                         probably damaging   29                                   6.30           10:122664879   CGC-CaC               p.Arg1081His       SCZ          M     trio_011
  *DPYD*        SNV             NS                                         probably damaging   125                                  3.89           1:97981407     GGA-aGA               p.Gly539Arg        SCZ          M     trio_016
  *OR4C46*      SNV             NS                                         probably damaging   125                                  1.61           11:51515885    GGA-aGA               p.Gly202Arg        SCZ          F     trio_019
  *UGT1A3*      SNV             NS                                         probably damaging   15                                   0.53           2:234637866    TTG-aTG               p.Leu32Met         SCZ          F     trio_023
  *FAM3D*       SNV             NS                                         probably damaging   194                                  1.18           3:58622886     TAC-TgC               p.Tyr147Cys        SCZ          M     trio_024
  *KLF12*       SNV             NS                                         probably damaging   112                                  6.02           13:74289537    TCT-TgT               p.Ser45Cys         SCZ          M     trio_033
  *ADCY7*       SNV             NS                                         probably damaging   56                                   4.93           16:50349011    AGC-gGC               p.Ser1020Gly       SCZ          M     trio_038
  *GPR153*      SNV             NS                                         probably damaging   89                                   5.80           1:6314661      ACC-AtC               p.Thr102Ile        SCZAFF-dpr   M     trio_040
  *PML*         SNV             NS                                         probably damaging   81                                   2.93           15:74290439    ACG-AtG               p.Thr75Met         SCZAFF-dpr   M     trio_044
  *SLC26A8*     SNV             NS                                         probably damaging   56                                   1.87           6:35927251     GAG-aAG               p.Glu512Lys        SCZAFF-bp    F     trio_077
  *CCDC108*     SNV             NS                                         probably damaging   46                                   2.43           2:219900235    AAT-AgT               p.Asn105Ser        SCZ          F     trio_080
  *TRAK1*       SNV             NS                                         probably damaging   29                                   4.80           3:42261055     CAT-CgT               p.His678Arg        SCZ          F     trio_083
  *FASTKD5*     SNV             NS                                         probably damaging   60                                   5.61           20:3128479     GCA-GgA               p.Ala413Gly        SCZ          M     trio_089
  *DGCR2*       SNV             NS                                         probably damaging   103                                  6.24           22:19028681    CCT-CgT               p.Pro429Arg        SCZ          M     trio_091
  *ACOT6*       SNV             NS                                         possibly damaging   194                                  -0.08          14:74086428    TAT-TgT               p.Tyr170Cys        SCZ          F     trio_047
  *PITPNM1*     SNV             NS/SPLICE[a](#TFN3){ref-type="table-fn"}   probably damaging   101                                  0.30           11:67267884    CGG-tGG               p.Arg217Trp        SCZ          M     trio_039
  *NPRL2*       SNV             NS/SPLICE[b](#TFN4){ref-type="table-fn"}   possibly damaging   56                                   6.11           3:50385987     GGC-aGC               p.Gly231Ser        SCZ          F     trio_023
  *MAGEC1*      SNV             NS                                         unknown             58                                   0.37           X:140993957    ACT-AgT               p.Thr256Ser        SCZ          M     trio_003
  *TRRAP*       SNV             NS                                         unknown             21                                   5.12           7:98498329     ATC-tTC               p.Ile295Phe        SCZ          M     trio_033
  *COL3A1*      SNV             NS/SPLICE[c](#TFN5){ref-type="table-fn"}   unknown             155                                  2.54           2:189851792    TCT-TtT               p.Ser152Phe        SCZ          M     trio_089
  *GIF*         SNV             NS                                         benign              29                                   0.83           11:59603474    GTA-aTA               p.Val294Ile        SCZAFF-dpr   F     trio_001
  *TEKT5*       SNV             NS                                         benign              89                                   0.25           16:10783119    ATC-AcC               p.Ile237Thr        SCZ          M     trio_011
  *THBS1*       SNV             NS                                         benign              56                                   5.66           15:39881442    GAG-aAG               p.Glu605Lys        SCZ          M     trio_015
  *PAG1*        SNV             NS                                         benign              29                                   0.15           8:81905378     GTC-aTC               p.Val29Ile         SCZ          M     trio_020
  *RGS12*       SNV             NS                                         benign              98                                   0.06           4:3429844      CCA-CtA               p.Pro518Leu        SCZAFF-dpr   M     trio_040
  *SAP30BP*     SNV             NS                                         benign              56                                   5.37           17:73702542    GGC-aGC               p.Gly274Ser        SCZ          F     trio_047
  *ZNF530*      SNV             NS                                         benign              46                                   -0.04          19:58118122    AGT-AaT               p.Ser410Asn        SCZAFF-bp    F     trio_077
  *MTOR*        SNV             NS                                         benign              46                                   2.82           1:11293489     AAT-AgT               p.Asn796Ser        SCZ          F     trio_080
  *INPP5A*      SNV             NS                                         benign              64                                   2.62           10:134463942   GCG-GtG               p.Ala80Val         SCZAFF-bp    F     trio_093
  *EDEM2*       SNV             NS                                         benign              83                                   3.39           20:33703457    TAC-cAC               p.Tyr469His        SCZ          M     trio_095
  *CELF2*       SNV             S/SPLICE[d](#TFN6){ref-type="table-fn"}    coding-synon                                             3.06           10:11356223    GGT-GGc               p.Gly345Gly        SCZ          M     trio_016
  *SLC26A7*     SNV             S                                          coding-synon                                             0.03           8:92346630     CAG-CAa               p.Gln250Gln        SCZ          M     trio_094
  *VPS35*       SNV             SPLICE[e](#TFN7){ref-type="table-fn"}                          \-                                   \-             16:46705610    C/T                                      SCZ          M     trio_002
  *ADAMTS3*     SNV             SPLICE[f](#TFN8){ref-type="table-fn"}                          \-                                   \-             4:73185683     G/A                                      SCZ          F     trio_023
  *GPR115*      DNV             NS                                         probably damaging   99                                   3.35           6:47682855     CTC-aaC               p.Leu625Asn        SCZ          F     trio_080
  *SPATA5*      IN/DEL          AA DELETION                                damaging            215[g](#TFN9){ref-type="table-fn"}   \-             4:123855728    TTCTT-caa-CAACA                          SCZ          F     trio_023
  *RB1CC1*      IN/DEL          FRAMESHIFT DELETION                        damaging            215                                  \-             8:53568705     ACTGT-tc-TCTGT                           SCZ          M     trio_026
  *LAMA2*       IN/DEL          FRAMESHIFT DELETION                        damaging            215                                  \-             6:129835668    GGTGG-aagccca-AAGCC                      SCZ          M     trio_092
  *ESAM*        IN/DEL          FRAMESHIFT INSERTION                       damaging            215                                  \-             11:124626163   tggac-AGCG-agcgg                         SCZ          M     trio_042

NS = Non-synonymous; S = Synonymous; SNV = single nucleotide variant; DNV = dinucleotide variant; SCZ = schizophrenia; SCZAFF-dpr = schizoaffective disorder depressed subtype; SCZAFF-bp = schizoaffective disorder bipolar subtype; M = Male; F = Female

HSF variation (%) between the reference and mutant sites:

−2.48;

56.53;

−0.68;

−34.92;

0;

−8.14

Maximum Grantham score (215) was used for the in/dels

###### 

NS/S ratio comparison between *de novo* and rare inherited mutations in SCZ trios

                                Cases   Controls                                                      
  ----------------------------- ------- ---------- ------ ------ -------- ------ ------ ------ ------ ------
                                                                                                      
  *de novo* mutations           34      32         2      16              7      4      3      1.33   
  novel inherited mutations     14378   8867       5511   1.61   0.0002   6213   3825   2388   1.60   0.81
  private inherited mutations   6727    4223       2504   1.69   0.0003   3079   1956   1123   1.74   0.73

S = Synonymous mutations

NS = Non-synonymous mutations
